Derma Sciences and Comvita to Move Forward with MEDIHONEY(TM) Product Line
Business Wire, 8/14/2007
Derma Sciences, Inc. (OTCBB: DSCI), a manufacturer and marketer of advanced wound care products, today announced that it and its partner, Comvita New Zealand, Ltd, are changing the brand name of their honey-based product line to MEDIHONEY(TM), effective immediately.
Previously, both companies had intended to market the products under the API-MED(TM) brand. The MEDIHONEY(TM) brand is an asset Comvita acquired through its recent purchase of Medihoney-Pty Ltd., formerly a subsidiary of the Australian-based Capilano group. MEDIHONEY(TM) is the market-leading line of Active Leptospermum honey-based wound and burn dressings, and is currently sold throughout Europe, Australia, and New Zealand. The brand has been featured in multiple peer-reviewed journal articles on the use of honey for the management of wounds and burns, with several additional articles set to be published in the fall of 2007.
Ed Quilty, CEO of Derma Sciences, said "This is an important step in the development of our Active Manuka (Leptospermum)-based product line. The clinical staff running the MEDIHONEY(TM) brand has done an excellent job facilitating the creation of a solid base of evidence, including randomized controlled trials that have been published in multiple peer-reviewed journals. Additionally, their expansive ongoing clinical development program will be a huge asset as we move forward with the commercialization of our products. Lastly, as we consider our strategy for filing an IND in the US for our product as a drug, the MEDIHONEY(TM) patented formulation will provide a good level of protection of this asset moving forward."
Brett Hewlett, CEO of Comvita, added "Leveraging the MEDIHONEY(TM) brand is a key reason for our acquisition of the company. We now have a full library of clinical evidence supporting the use of some of our key products, and a great foundation of clinical activity currently underway upon which to build."…
Business Wire, 8/14/2007
Derma Sciences, Inc. (OTCBB: DSCI), a manufacturer and marketer of advanced wound care products, today announced that it and its partner, Comvita New Zealand, Ltd, are changing the brand name of their honey-based product line to MEDIHONEY(TM), effective immediately.
Previously, both companies had intended to market the products under the API-MED(TM) brand. The MEDIHONEY(TM) brand is an asset Comvita acquired through its recent purchase of Medihoney-Pty Ltd., formerly a subsidiary of the Australian-based Capilano group. MEDIHONEY(TM) is the market-leading line of Active Leptospermum honey-based wound and burn dressings, and is currently sold throughout Europe, Australia, and New Zealand. The brand has been featured in multiple peer-reviewed journal articles on the use of honey for the management of wounds and burns, with several additional articles set to be published in the fall of 2007.
Ed Quilty, CEO of Derma Sciences, said "This is an important step in the development of our Active Manuka (Leptospermum)-based product line. The clinical staff running the MEDIHONEY(TM) brand has done an excellent job facilitating the creation of a solid base of evidence, including randomized controlled trials that have been published in multiple peer-reviewed journals. Additionally, their expansive ongoing clinical development program will be a huge asset as we move forward with the commercialization of our products. Lastly, as we consider our strategy for filing an IND in the US for our product as a drug, the MEDIHONEY(TM) patented formulation will provide a good level of protection of this asset moving forward."
Brett Hewlett, CEO of Comvita, added "Leveraging the MEDIHONEY(TM) brand is a key reason for our acquisition of the company. We now have a full library of clinical evidence supporting the use of some of our key products, and a great foundation of clinical activity currently underway upon which to build."…
No comments:
Post a Comment